Our Team

Management and Board

Sandy D. Der, PhD

COO, Co-Founder, Director

Sandy D. Der, PhD

COO, Co-Founder, Director

Dr. Sandy Der is a co-founder of ImmVue since its inception in 2017 and currently serves as COO. He was an assistant professor at the University of Toronto where his research areas included microbiology, immunology, genomics and cancer biology. Since 2015, he was a founding partner at Novatio Ventures with focus on investing in early stage biotechs in therapeutics, digital health and diagnostics.

John Kim, MD, FRCPC

Interim CMO, Director

John Kim, MD, FRCPC

Interim CMO, Director

Dr. John Kim is a GI and Head and Neck (H&N) radiation oncologist in the Radiation Medicine Program (RMP), Princess Margaret Cancer Centre, University Health Network and Department of Radiation Oncology, University of Toronto. He has more than 20 years of clinical outcomes research and clinical trials expertise. He has held numerous leadership positions including RMP Deputy Head; RMP Director, Clinical Strategies; inaugural Ontario Health Radiation Treatment Program Co-Chair H&N Communities of Practice; inaugural multidisciplinary Ontario H&N Cancers Lead; and NRG Oncology Clinical Trials Group H&N Liaison and Steering Cancer Committee member.

Jayan Nagendran, MD, PhD, FRCSC

Director

Jayan Nagendran, MD, PhD, FRCSC

Director

Dr. Jayan Nagendran is a cardiac surgeon and clinician-scientist, who trained in cardiothoracic transplant surgery at Stanford University. He is the Director of the Division of Cardiac Surgery at the University of Alberta, and Surgical Director of Lung Transplantation for the province. Dr. Nagendran attained a PhD in Experimental Medicine and has been a pioneer in thoracic organ preservation developing the Ex-Vivo Multi-Organ Perfusion Research Laboratory. He is an entrepreneur and was co-founder of Tevosol, a medical device company that developed the Ex-Vivo Organ Support System (EVOSS). Dr. Nagendran successfully completed a first in human investigator initiated clinical trial in lung transplantation with the technology used to develop EVOSS.

Joonsoo Kang, PhD

Co-Founder, Board Observer

Joonsoo Kang, PhD

Co-Founder, Board Observer

Joonsoo Kang investigates molecular mechanisms of T cell lineage fate choices and T cell homeostasis. A field of continuing interest in his lab is the interplay of the prototypical T cell costimulatory and checkpoint inhibitory molecules, CD28 and CTLA-4. His lab is one of the earliest to show distinct in vivo activities of CTLA-4 on different T cell subsets and the first to link ITK to CD28 signaling in vivo to regulate T cell trafficking to tissues. He is a member of the executive steering committee of the Immunological Genome Project.

David Moon, JD, MBA

CEO, Director

David Moon, JD, MBA

CEO, Director

David Moon has served as Chief Executive Officer of ImmVue since October 2023 and was an early investor. Mr. Moon is a serial entrepreneur with a track record for moving companies from their formative stages into commercialization or the next steps towards commercialization. His experiences span software, medical devices, consumer products and securities law.

Scientific Advisory Board

Leslie J. Berg, PhD

Co-Founder, Chair

Chair and Professor of Immunology and Microbiology, University of Colorado School of Medicine Anschutz, Distinguished Fellow of American Association of Immunologists

Matthew Krummel, PhD

Professor in the Department of Pathology, University of California San Francisco, Robert E. Smith Endowed Chair of Experimental Pathology, Chair of the Bakar ImmunoX Initiative, Founder and Partner at Foundery Innovations LP

Andrea Reboldi, PhD

Associate Professor, Department of Pathology, University of Massachusetts Chan Medical School, Burroughs Wellcome Fund Fellow, Pathogenesis of Infectious Disease

Andrea Schietinger, PhD

Memorial Sloan Kettering Cancer Institute, Catherine and Frederick R. Adler Chair for Junior Faculty, National Institutes of Health Director’s New Innovator Awardee

Arlene Sharpe MD, PhD

Kolokotrones University Professor at Harvard University, Chair, Department of Immunology at Harvard Medical School, Leader of the Cancer Immunology Program at Dana-Farber/Harvard Cancer Center, Vice Director of the Gene Lay Institute of Immunology and Inflammation at Brigham and Women’s Hospital, Massachusetts General Hospital, and Harvard Medical School

Barry Sleckman, MD, PhD

Professor of Medicine, University of Alabama at Birmingham, Director of the O’Neal Comprehensive Cancer Center, Member of American Society of Clinical Investigation, Association of American Physicians, Fellow in the American Academy for the Advancement of Science